immatics biotechnologies GmbH
NASDAQ Capital MarketTotal Valuation
immatics biotechnologies GmbH carries a market capitalization of 72,922.00, placing it among publicly traded companies globally. Its enterprise value stands at -378.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 72,922.00 |
| Enterprise Value | -378.74M |
Share Statistics
immatics biotechnologies GmbH currently has 136.67M shares outstanding.
| Shares Outstanding | 136.67M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
immatics biotechnologies GmbH maintains a current ratio of 7.54, meaning it holds 7.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.65, indicating elevated leverage, while an interest coverage ratio of -247.43 demonstrates limited ability to service its debt obligations.
| Current Ratio | 7.54 |
| Quick Ratio | 7.02 |
| Debt / Equity | 3.65 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | -247.43 |
Financial Efficiency
| Return on Equity (ROE) | -47.80 |
| Return on Assets (ROA) | -39.23 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -215,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
immatics biotechnologies GmbH's stock has declined approximately -99.98013% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.71.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.98013% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.71 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -214.77M, while operating income came in at -226.78M.
| Revenue | 41.70M |
| Gross Profit | N/A |
| Operating Income | -226.78M |
| Pretax Income | -206.76M |
| Net Income | -206.55M |
| EBITDA | -214.77M |
| EBIT | -226.78M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
immatics biotechnologies GmbH holds 393.35M in cash and equivalents against 14.61M in total debt, resulting in a net debt position of -232.46M. Total book value stands at 399.63M, with working capital of 372.24M providing operational flexibility.
| Cash & Cash Equivalents | 393.35M |
| Total Debt | 14.61M |
| Net Debt | -232.46M |
| Equity (Book Value) | 399.63M |
| Book Value Per Share | 2.92 |
| Working Capital | 372.24M |
Cash Flow
immatics biotechnologies GmbH produced -205.87M in operating cash flow over the past twelve months.
| Operating Cash Flow | -205.87M |
| Capital Expenditures | -3.75M |
| Free Cash Flow | -209.61M |
| FCF Per Share | N/A |
Margins
immatics biotechnologies GmbH operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -543.79 and net profit margin of -495.27 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -543.79 |
| Pretax Margin | -495.79 |
| Profit Margin | -495.27 |
| EBITDA Margin | -514.99 |
Scores
immatics biotechnologies GmbH posts an Altman Z-Score of -3.16, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.16 |